264 related articles for article (PubMed ID: 31954535)
21. Epidemiology of low-grade serous ovarian cancer.
Plaxe SC
Am J Obstet Gynecol; 2008 Apr; 198(4):459.e1-8; discussion 459.e8-9. PubMed ID: 18395040
[TBL] [Abstract][Full Text] [Related]
22. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Epidemiology and Risk Factors of Relapse, Follow-up and Interest of a Completion Surgery].
Margueritte F; Sallee C; Lacorre A; Gauroy E; Larouzee E; Chereau E; De La Motte Rouge T; Koskas M; Gauthier T
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):248-259. PubMed ID: 32004784
[TBL] [Abstract][Full Text] [Related]
23. Advances in precision therapy of low-grade serous ovarian cancer: A review.
Wang Q; Cao SH; Li YY; Zhang JB; Yang XH; Zhang B
Medicine (Baltimore); 2024 Apr; 103(17):e34306. PubMed ID: 38669365
[TBL] [Abstract][Full Text] [Related]
24. Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
Gershenson DM; Cobb LP; Westin SN; Zhang Y; Jazaeri A; Malpica A; Sun CC
Gynecol Oncol; 2022 Nov; 167(2):139-145. PubMed ID: 36137845
[TBL] [Abstract][Full Text] [Related]
25. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study.
Zhou J; He ZY; Li FY; Sun JY; Lin HX; Wu SG; Chen QH
Oncotarget; 2016 Feb; 7(7):7952-9. PubMed ID: 26788911
[TBL] [Abstract][Full Text] [Related]
27. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Short Text].
Bourdel N; Huchon C; Cendos AW; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chéreau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):223-235. PubMed ID: 32004780
[TBL] [Abstract][Full Text] [Related]
28. Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma.
Stewart LM; Stewart CJR; Spilsbury K; Cohen PA; Jordan S
Gynecol Oncol; 2020 Mar; 156(3):611-615. PubMed ID: 31983516
[TBL] [Abstract][Full Text] [Related]
29. Factors associated with the involvement of lymph nodes in low-grade serous ovarian cancer.
Durmuş Y; Meydanlı MM; Akıllı H; Kayıkçıoğlu F; Güngördük K; Akbayır Ö; Taşkın S; Çelik H; Ayhan A
J Surg Oncol; 2022 Feb; 125(2):264-272. PubMed ID: 34610148
[TBL] [Abstract][Full Text] [Related]
30. Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers.
Di Lorenzo P; Conteduca V; Scarpi E; Adorni M; Multinu F; Garbi A; Betella I; Grassi T; Bianchi T; Di Martino G; Amadori A; Maniglio P; Strada I; Carinelli S; Jaconi M; Aletti G; Zanagnolo V; Maggioni A; Savelli L; De Giorgi U; Landoni F; Colombo N; Fruscio R
Front Oncol; 2022; 12():970918. PubMed ID: 36237308
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review.
Lazurko C; Linder R; Pulman K; Lennox G; Feigenberg T; Fazelzad R; May T; Zigras T
Curr Oncol; 2023 Sep; 30(9):8159-8171. PubMed ID: 37754507
[TBL] [Abstract][Full Text] [Related]
32. A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006.
Hannibal CG; Vang R; Junge J; Kjaerbye-Thygesen A; Kurman RJ; Kjaer SK
Gynecol Oncol; 2012 Jun; 125(3):655-60. PubMed ID: 22370600
[TBL] [Abstract][Full Text] [Related]
33. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
[TBL] [Abstract][Full Text] [Related]
34. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.
Ayhan A; Ozkan NT; Sarı ME; Celik H; Dede M; Akbayır Ö; Güngördük K; Şahin H; Haberal A; Güngör T; Arvas M; Meydanlı MM
J Gynecol Oncol; 2018 Jan; 29(1):e12. PubMed ID: 29185270
[TBL] [Abstract][Full Text] [Related]
35. Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum.
Grisham RN; Chui MH
Curr Oncol Rep; 2022 Nov; 24(11):1549-1555. PubMed ID: 35962920
[TBL] [Abstract][Full Text] [Related]
36. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk.
Vasconcelos I; de Sousa Mendes M
Eur J Cancer; 2015 Mar; 51(5):620-31. PubMed ID: 25661104
[TBL] [Abstract][Full Text] [Related]
37. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
[TBL] [Abstract][Full Text] [Related]
38. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Therapeutic Management of Early Stages].
Canlorbe G; Lecointre L; Chauvet P; Azaïs H; Fauvet R; Uzan C
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):287-303. PubMed ID: 32004786
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708).
Chung YS; Park SY; Lee JY; Park JY; Lee JW; Kim HS; Suh DS; Kim YH; Lee JM; Kim M; Choi MC; Shim SH; Lee KH; Song T; Hong JH; Lee WM; Lee B; Lee IH
BMC Cancer; 2019 Apr; 19(1):341. PubMed ID: 30971221
[TBL] [Abstract][Full Text] [Related]
40. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]